{
  "Clinical Information": [],
  "Patent Information": [],
  "Sequence Information": {
    "ID": "AP02876",
    "Peptide Name": "Dhvar4 (Lys-rich; Leu-rich; UCLL1; histatin 5 analog, synthetic AMPs20)",
    "Source": "sequence truncation, histatin-derived,",
    "Family": "Not found",
    "Gene": "Not found",
    "Sequence": "KRLFKKLLFSLRKY",
    "Sequence Length": 14,
    "UniProt Entry": "Ref",
    "Protein Existence": "Not found",
    "Biological Activity": [
      "Anti-Gram+",
      "Gram-",
      "Antifungal",
      "candidacidal",
      "Antibiofilm"
    ],
    "Target Organism": "Not found",
    "Hemolytic Activity": "Not found",
    "Cytotoxicity": "Not found",
    "Binding Target": "Not found",
    "Linear/Cyclic": "Not found",
    "N-terminal Modification": "Not found",
    "C-terminal Modification": "Not found",
    "Nonterminal Modifications and Unusual Amino Acids": "Not found",
    "Stereochemistry": "Not found",
    "Structure": "Helix",
    "Structure Description": "Not found",
    "Helical Wheel Diagram": "Not found",
    "PDB ID": "",
    "Predicted Structure": "Not found",
    "Formula": "Not found",
    "Absent Amino Acids": "Not found",
    "Common Amino Acids": "Not found",
    "Mass": "Not found",
    "PI": "Not found",
    "Basic Residues": "Not found",
    "Acidic Residues": "Not found",
    "Hydrophobic Residues": "Not found",
    "Net charge": 6,
    "Boman Index": 2.13,
    "Hydrophobicity": "Not found",
    "Aliphatic Index": "Not found",
    "Half Life": "Not found",
    "Extinction Coefficient Cystines": "Not found",
    "Absorbance 280nm": "Not found",
    "Polar Residues": "Not found",
    "Function": "Not found",
    "Hydrophobic residue%": "43%",
    "Crucial residues": ""
  },
  "Literature Information": {
    "Literature": "Sequence analysis: APD analysis reveals that the sequence of this peptide shows 53.3% similarity toBP100. A peptide derivative of C-terminal 14 residues of human salivary histatin 5.Activity:  Active against amphotericin B-resistant C. albicans, C. neoformans 316, C. krusei 355, C. parapsilosis 356, and a fluconazole-resistant C. glabrata B57149 isolate (IC50 0.7-2.4 uM). Also active against prosthetic microorganisms, including C. tropicalis GB 9/9, C. albicans GBJ 13/4A, C. krusei GBJ 18/4A, C. humicola GBJ 1/4A, S. anginosus GBJ 27/5C,  S. salivarius GV 24/9, R. dentocariosa GBJ 41/25B, S. aureus GB 2/1, S. epidermidis GB 9/6, S. mucilaginosus GB 16/3, E. faecium 603, E. coli at 4 ug/mL(Elving et al., 2000).  S. aureus (MIC 16 uM), B. subtilis (MIC 8 uM), M. luteus (MIC 16 uM), E. coli (MIC 32 uM), P. vulgaris (MIC 16 uM), and P. aeruginosa (MIC 32 uM) (Yang et al., 2023.Updated 7/2021; 12/2024",
    "Author": "Helmerhorst EJ1, Reijnders IM, van't Hof W, Simoons-Smit I, Veerman EC, Amerongen AV.",
    "Reference": "Antimicrob Agents Chemother. 1999 Mar;43(3):702-4.PubMed",
    "Title": "Amphotericin B- and fluconazole-resistant Candida spp., Aspergillus fumigatus, and other newly emerging pathogenic fungi are susceptible to basic antifungal peptides"
  },
  "3D Structure": []
}